Global Pharmaceutical Intelligence

Oncology · Rare Diseases · Market Access · Policy Strategy

FDA · EMA · NMPA · Global Biopharma Markets

DengYueMed delivers independent insights on drug innovation, regulatory strategy, and pharmaceutical market access.

Explore Drug Database →

Drug Intelligence

Enhertu

ADC HER2 FDA

Zongertinib

TKI HER2

Sevabertinib

TKI China

Zynteglo

Gene Therapy β-thalassemia

View Full Drug Database →

Featured Analysis

Advances in the Treatment of HER2-Mutant Advanced Non-Small Cell Lung Cancer

April 17, 2026

Advances in the Treatment of HER2-Mutant Advanced Non-Small Cell Lung Cancer

From Single-Target Inhibition to Network-Level Intervention: A Paradigm Shift in KRAS-Mutant Cancer Therapy

April 16, 2026

Covering Nearly 20 Rare Diseases: A Comprehensive Overview of Newly Approved Rare Disease Drugs Worldwide in March 2026

April 16, 2026

China Innovative Drug Weekly: RNA, ADC, CAR-T and GLP-1 Drive Global Expansion

April 15, 2026

Latest Insights

Advances in the Treatment of HER2-Mutant Advanced Non-Small Cell Lung Cancer

April 17, 2026

From Single-Target Inhibition to Network-Level Intervention: A Paradigm Shift in KRAS-Mutant Cancer Therapy

April 16, 2026

Covering Nearly 20 Rare Diseases: A Comprehensive Overview of Newly Approved Rare Disease Drugs Worldwide in March 2026

April 16, 2026

China Innovative Drug Weekly: RNA, ADC, CAR-T and GLP-1 Drive Global Expansion

April 15, 2026

Latest Advances in Gene Therapy: From Genetic Disorders to Cancer Treatment

April 15, 2026

Chinese-Listed Pharmaceuticals Going Global: New Trends in the International Accessibility of Specialty Drugs

April 14, 2026